G Bernhard Landwehrmeyer

List of Publications by Year
in descending order

176 papers	12,891 citations	31949 53 h-index	27389 106 g-index
185 all docs	185 docs citations	185 times ranked	11739 citing authors

#	Article	IF	Citations
1	Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurology, The, 2009, 8, 791-801.	4.9	856
2	Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data. Lancet Neurology, The, 2013, 12, 637-649.	4.9	704
3	Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 3498-3503.	3.3	666
4	Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis. Lancet Neurology, The, 2011, 10, 31-42.	4.9	530
5	Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis. Nature Genetics, 2016, 48, 1043-1048.	9.4	494
6	Targeting Huntingtin Expression in Patients with Huntingtonâ€™s Disease. New England Journal of Medicine, 2019, 380, 2307-2316.	13.9	493
7	Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data. Lancet Neurology, The, 2012, 11, 42-53.	4.9	479
8	Proteases Acting on Mutant Huntingtin Generate Cleaved Products that Differentially Build Up Cytoplasmic and Nuclear Inclusions. Molecular Cell, 2002, 10, 259-269.	4.5	356
9	Transgenic rat model of Huntington's disease. Human Molecular Genetics, 2003, 12, 617-624.	1.4	329
10	CAG Repeat Not Polyglutamine Length Determines Timing of Huntingtonâ€™s Disease Onset. Cell, 2019, 178, 887-900.e14.	13.5	301
11	Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study. Lancet Neurology, The, 2017, 16, 701-711.	4.9	248
12	Neuropsychiatric symptoms in a European Huntington's disease cohort (REGISTRY). Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 1411-1418.	0.9	237
13	Five siRNAs Targeting Three SNPs May Provide Therapy for Three-Quarters of Huntington's Disease Patients. Current Biology, 2009, 19, 774-778.	1.8	227
14	Huntington's disease gene: Regional and cellular expression in brain of normal and affected individuals. Annals of Neurology, 1995, 37, 218-230.	2.8	206
15	An Isoform of Ataxinâ€3 Accumulates in the Nucleus of Neuronal Cells in Affected Brain Regions of SCA3 Patients. Brain Pathology, 1998, 8, 669-679.	2.1	189
16	Differential expression of mGluR5 metabotropic glutamate receptor mRNA by rat striatal neurons. Journal of Comparative Neurology, 1995, 354, 241-252.	0.9	178
17	Mitochondrial impairment in patients and asymptomatic mutation carriers of Huntington's disease. Movement Disorders, 2005, 20, 674-679.	2.2	162
18	Expression of NMDAR2D glutamate receptor subunit mRNA in neurochemically identified interneurons in the rat neostriatum, neocortex and hippocampus. Molecular Brain Research, 1996, 42, 89-102.	2.5	161

#	Article	IF	Citations
19	Riluzole in Huntington's disease: a 3â€year, randomized controlled study. Annals of Neurology, 2007, 62, 262-272.	2.8	160
20	Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Neurology, The, 2011, 10, 1049-1057.	4.9	157
21	Thalamic Atrophy in Huntington's Disease Co-varies with Cognitive Performance: A Morphometric MRI Analysis. Cerebral Cortex, 2005, 15, 846-853.	1.6	150
22	Localization of metabotropic glutamate receptor 7 mRNA and mGluR7a protein in the rat basal ganglia. , 1999, 415, 266-284.		138
23	A single nucleotide polymorphism in the coding region of PGC-1Î± is a male-specific modifier of Huntington disease age-at-onset in a large European cohort. BMC Neurology, 2014, 14, 1.	0.8	137
24	Dorsolateral prefrontal cortex dysfunction in presymptomatic Huntington's disease: evidence from event-related fMRI. Brain, 2007, 130, 2845-2857.	3.7	131
25	An exploratory doubleâ€blind, randomized clinical trial with selisistat, a <scp>SirT1</scp> inhibitor, in patients with <scp>H</scp>untington's disease. British Journal of Clinical Pharmacology, 2015, 79, 465-476.	1.1	128
26	Observing Huntingtonâ€™s Disease: the European Huntingtonâ€™s Disease Networkâ€™s REGISTRY. PLOS Currents, 2010, 2, RRN1184.	1.4	124
27	Compensation in Preclinical Huntington's Disease: Evidence From the Track-On HD Study. EBioMedicine, 2015, 2, 1420-1429.	2.7	122
28	Neuropsychiatric symptoms are very common in premanifest and early stage Huntington's Disease. Parkinsonism and Related Disorders, 2016, 25, 58-64.	1.1	122
29	Expression of N-Methyl-D-Aspartate receptor subunit mRNAs in the human brain: Hippocampus and cortex. , 1998, 390, 75-90.		120
30	The gene coding for PGC-1Î± modifies age at onset in Huntington's Disease. Molecular Neurodegeneration, 2009, 4, 3.	4.4	119
31	Biological and clinical manifestations of juvenile Huntington's disease: a retrospective analysis. Lancet Neurology, The, 2018, 17, 986-993.	4.9	115
32	MSH3 modifies somatic instability and disease severity in Huntingtonâ€™s and myotonic dystrophy type 1. Brain, 2019, 142, 1876-1886.	3.7	114
33	Riluzole prolongs survival time and alters nuclear inclusion formation in a transgenic mouse model of Huntington's disease. Movement Disorders, 2002, 17, 748-757.	2.2	108
34	Aberrant connectivity of lateral prefrontal networks in presymptomatic Huntington's disease. Experimental Neurology, 2008, 213, 137-144.	2.0	104
35	The influence of gender on phenotype and disease progression in patients with Huntington's disease. Parkinsonism and Related Disorders, 2013, 19, 192-197.	1.1	96
36	Selective vulnerability of Rich Club brain regions is an organizational principle of structural connectivity loss in Huntingtonâ€™s disease. Brain, 2015, 138, 3327-3344.	3.7	96

#	Article	IF	Citations
37	Polyâ€<scp>GP</scp> in cerebrospinal fluid links C9orf72â€associated dipeptide repeat expression to the asymptomatic phase of <scp>ALS</scp>/<scp>FTD</scp>. EMBO Molecular Medicine, 2017, 9, 859-868.	3.3	90
38	Chitotriosidase (CHIT1) is increased in microglia and macrophages in spinal cord of amyotrophic lateral sclerosis and cerebrospinal fluid levels correlate with disease severity and progression. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 239-247.	0.9	89
39	Myopathy as a first symptom of Huntington's disease in a Marathon runner. Movement Disorders, 2007, 22, 1637-1640.	2.2	86
40	A greatly extended PPARGC1A genomic locus encodes several new brain-specific isoforms and influences Huntington disease age of onsetâ€. Human Molecular Genetics, 2012, 21, 3461-3473.	1.4	85
41	Serum neurofilament light chain in behavioral variant frontotemporal dementia. Neurology, 2018, 91, e1390-e1401.	1.5	85
42	Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study. Lancet Neurology, The, 2019, 18, 165-176.	4.9	82
43	Impaired Regulation of Brain Mitochondria by Extramitochondrial Ca2+ in Transgenic Huntington Disease Rats. Journal of Biological Chemistry, 2008, 283, 30715-30724.	1.6	76
44	Suicidal ideation in a European Huntington's disease population. Journal of Affective Disorders, 2013, 151, 248-258.	2.0	74
45	Neurofilament as a blood marker for diagnosis and monitoring of primary progressive aphasias. Neurology, 2017, 88, 961-969.	1.5	73
46	Cortical dysfunction in patients with Huntington's disease during working memory performance. Human Brain Mapping, 2009, 30, 327-339.	1.9	72
47	Specific serum and CSF microRNA profiles distinguish sporadic behavioural variant of frontotemporal dementia compared with Alzheimer patients and cognitively healthy controls. PLoS ONE, 2018, 13, e0197329.	1.1	68
48	Global cerebral atrophy in early stages of HuntingtonÊ¼s disease: quantitative MRI study. NeuroReport, 2004, 15, 363-365.	0.6	67
49	A randomized, placeboâ€controlled trial of AFQ056 for the treatment of chorea in Huntington's disease. Movement Disorders, 2015, 30, 427-431.	2.2	67
50	Body weight is a robust predictor of clinical progression in Huntington disease. Annals of Neurology, 2017, 82, 479-483.	2.8	67
51	Movement Disorder Society Task Force Viewpoint: Huntington's Disease Diagnostic Categories. Movement Disorders Clinical Practice, 2019, 6, 541-546.	0.8	67
52	Default-mode network changes in preclinical Huntington's disease. Experimental Neurology, 2012, 237, 191-198.	2.0	64
53	Association between caffeine intake and age at onset in Huntington's disease. Neurobiology of Disease, 2013, 58, 179-182.	2.1	63
54	Update on Huntington's disease: Advances in care and emerging therapeutic options. Parkinsonism and Related Disorders, 2015, 21, 169-178.	1.1	61

#	Article	IF	Citations
55	Expression of N-Methyl-D-Aspartate receptor subunit mRNAs in the human brain: Striatum and globus pallidus. Journal of Comparative Neurology, 1998, 390, 63-74.	0.9	60
56	Transgenic rat model of Huntington's disease. Human Molecular Genetics, 2003, 12, 617-624.	1.4	58
57	Immunohistochemical analysis of KCNQ3 potassium channels in mouse brain. Neuroscience Letters, 2006, 400, 101-104.	1.0	54
58	Magnetic resonance perfusion imaging of resting-state cerebral blood flow in preclinical Huntington's disease. Journal of Cerebral Blood Flow and Metabolism, 2011, 31, 1908-1918.	2.4	54
59	Expression Analysis of Ataxinâ€7 mRNA and Protein in Human Brain: Evidence for a Widespread Distribution and Focal Protein Accumulation. Brain Pathology, 2000, 10, 385-394.	2.1	53
60	Timing and Impact of Psychiatric, Cognitive, and Motor Abnormalities in Huntington Disease. Neurology, 2021, 96, e2395-e2406.	1.5	53
61	Immunohistochemical analysis of KCNQ2 potassium channels in adult and developing mouse brain. Brain Research, 2006, 1077, 1-6.	1.1	52
62	High-Capacity Adenoviral Vector-Mediated Reduction of Huntingtin Aggregate Load In Vitro and In Vivo. Human Gene Therapy, 2007, 18, 303-311.	1.4	52
63	Brain activation and functional connectivity in premanifest Huntington's disease during states of intrinsic and phasic alertness. Human Brain Mapping, 2012, 33, 2161-2173.	1.9	49
64	The contribution of gender differences in motor, behavioral and cognitive features to functional capacity, independence and quality of life in patients with Huntington's disease. Parkinsonism and Related Disorders, 2018, 49, 42-47.	1.1	46
65	Longitudinal functional magnetic resonance imaging of cognition in preclinical Huntington's disease. Experimental Neurology, 2011, 231, 214-222.	2.0	45
66	Cerebellar abnormalities in Huntington's disease: A role in motor and psychiatric impairment?. Movement Disorders, 2014, 29, 1648-1654.	2.2	45
67	Differential pattern of brainâ€specific CSF proteins tau and amyloidâ€beta in Parkinsonian syndromes. Movement Disorders, 2010, 25, 1284-1288.	2.2	44
68	Association of CAG Repeats With Long-term Progression in Huntington Disease. JAMA Neurology, 2019, 76, 1375.	4.5	44
69	The neuroanatomy of subthreshold depressive symptoms in Huntington's disease: a combined diffusion tensor imaging (DTI) and voxel-based morphometry (VBM) study. Psychological Medicine, 2014, 44, 1867-1878.	2.7	43
70	A randomized exploratory phase 2 study in patients with chemotherapy-related peripheral neuropathy evaluating whole-body vibration training as adjunct to an integrated program including massage, passive mobilization and physical exercises. Experimental Hematology and Oncology, 2017, 6, 5.	2.0	43
71	Bupropion for the treatment of apathy in Huntingtonâ€™s disease: A multicenter, randomised, double-blind, placebo-controlled, prospective crossover trial. PLoS ONE, 2017, 12, e0173872.	1.1	43
72	Predicting primary progressive aphasias with support vector machine approaches in structural MRI data. NeuroImage: Clinical, 2017, 14, 334-343.	1.4	42

#	Article	IF	Citations
73	A Europeâ€wide assessment of current medication choices in Huntington's disease. Movement Disorders, 2008, 23, 1788-1788.	2.2	40
74	Visual system integrity and cognition in early Huntington's disease. European Journal of Neuroscience, 2014, 40, 2417-2426.	1.2	40
75	Atrophy in the Thalamus But Not Cerebellum Is Specific for C9orf72 FTD and ALS Patients â€“ An Atlas-Based Volumetric MRI Study. Frontiers in Aging Neuroscience, 2018, 10, 45.	1.7	40
76	Imaging of activated microglia with PET and [11 C]PK 11195 in corticobasal degeneration. Movement Disorders, 2004, 19, 817-821.	2.2	39
77	Abnormal cerebellar volume and corticocerebellar dysfunction in early manifest Huntingtonâ€™s disease. Journal of Neurology, 2015, 262, 859-869.	1.8	39
78	Factor analysis of behavioural symptoms in Huntington's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 411-412.	0.9	38
79	Caudate Nucleus and Insular Activation During a Pain Suppression Paradigm Comparing Thermal and Electrical Stimulation. Open Neuroimaging Journal, 2011, 5, 1-8.	0.2	37
80	What is the impact of education on Huntington's disease?. Movement Disorders, 2011, 26, 1489-1495.	2.2	34
81	Rate of change in early Huntington's disease: A clinicometric analysis. Movement Disorders, 2012, 27, 118-124.	2.2	34
82	Evaluation of multi-modal, multi-site neuroimaging measures in Huntington's disease: Baseline results from the PADDINGTON study. NeuroImage: Clinical, 2013, 2, 204-211.	1.4	34
83	Ethyl-eicosapentaenoic acid treatment in Huntington's disease: A placebo-controlled clinical trial. Movement Disorders, 2015, 30, 1426-1429.	2.2	33
84	Different CSF protein profiles in amyotrophic lateral sclerosis and frontotemporal dementia with C9orf72 hexanucleotide repeat expansion. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 503-511.	0.9	33
85	Overlap between age-at-onset and disease-progression determinants in Huntington disease. Neurology, 2018, 90, e2099-e2106.	1.5	32
86	Longitudinal Diffusion Tensor Imaging Shows Progressive Changes in White Matter in Huntingtonâ€™s Disease. Journal of Huntington's Disease, 2015, 4, 333-346.	0.9	31
87	Enroll-HD: An Integrated Clinical Research Platform and Worldwide Observational Study for Huntington's Disease. Frontiers in Neurology, 2021, 12, 667420.	1.1	31
88	Exome sequencing of individuals with Huntingtonâ€™s disease implicates FAN1 nuclease activity in slowing CAG expansion and disease onset. Nature Neuroscience, 2022, 25, 446-457.	7.1	31
89	Motor network structure and function are associated with motor performance in Huntingtonâ€™s disease. Journal of Neurology, 2016, 263, 539-549.	1.8	30
90	Modulation of cortical acetylcholine release by serotonin: the role of substance P interneurons. Naunyn-Schmiedeberg's Archives of Pharmacology, 1996, 354, 618-26.	1.4	29

#	Article	IF	Citations
91	Corpus Callosal Atrophy in Premanifest and Early Huntington's Disease. Journal of Huntington's Disease, 2013, 2, 517-526.	0.9	29
92	Genetic Risk Underlying Psychiatric and Cognitive Symptoms in Huntingtonâ€™s Disease. Biological Psychiatry, 2020, 87, 857-865.	0.7	29
93	Genetic modifiers of Huntington disease differentially influence motor and cognitive domains. American Journal of Human Genetics, 2022, 109, 885-899.	2.6	29
94	Evaluating multicenter DTI data in Huntington's disease on site specific effects: An ex post facto approach. NeuroImage: Clinical, 2013, 2, 161-167.	1.4	28
95	FDG-PET underscores the key role of the thalamus in frontotemporal lobar degeneration caused by C9ORF72 mutations. Translational Psychiatry, 2019, 9, 54.	2.4	28
96	Altered Ca2+ signaling in skeletal muscle fibers of the R6/2 mouse, a model of Huntingtonâ€™s disease. Journal of General Physiology, 2014, 144, 393-413.	0.9	27
97	The European Reference Network for Rare Neurological Diseases. Frontiers in Neurology, 2020, 11, 616569.	1.1	26
98	PET Molecular Imaging of Phosphodiesterase 10A: An Early Biomarker of Huntington's Disease Progression. Movement Disorders, 2020, 35, 606-615.	2.2	25
99	Patterns of age related changes for phosphodiesterase type-10A in comparison with dopamine D 2/3 receptors and sub-cortical volumes in the human basal ganglia: A PET study with 18 F-MNI-659 and 11 C-raclopride with correction for partial volume effect. NeuroImage, 2017, 152, 330-339.	2.1	24
100	IT15 gene expression in fetal human brain. Brain Research, 1994, 659, 33-41.	1.1	23
101	Clinico-genetic findings in 509 frontotemporal dementia patients. Molecular Psychiatry, 2021, 26, 5824-5832.	4.1	23
102	Discriminant Analysis of Beck Depression Inventory and Hamilton Rating Scale for Depression in Huntington's Disease. Journal of Neuropsychiatry and Clinical Neurosciences, 2011, 23, 399-402.	0.9	22
103	Short-interval observational data to inform clinical trial design in Huntington's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 1291-1298.	0.9	22
104	Quantifying progression in primary progressive aphasia with structural neuroimaging. Alzheimer's and Dementia, 2021, 17, 1595-1609.	0.4	22
105	Brain Structure in Preclinical Huntington's Disease: A Multi-Method Approach. Neurodegenerative Diseases, 2013, 12, 13-22.	0.8	21
106	Atrophy and structural covariance of the cholinergic basal forebrain in primary progressive aphasia. Cortex, 2016, 83, 124-135.	1.1	21
107	The neuropsychology of first impressions: Evidence from Huntington's disease. Cortex, 2016, 85, 100-115.	1.1	21
108	Discrepancies in reporting the CAG repeat lengths for Huntington's disease. European Journal of Human Genetics, 2012, 20, 20-26.	1.4	20

#	Article	IF	Citations
109	TAA repeat variation in the GRIK2 gene does not influence age at onset in Huntingtonâ€™s disease. Biochemical and Biophysical Research Communications, 2012, 424, 404-408.	1.0	20
110	Suicidal ideation and suicidal behavior according to the C-SSRS in a European cohort of Huntington's disease gene expansion carriers. Journal of Affective Disorders, 2018, 228, 194-204.	2.0	20
111	NMDA receptor gene variations as modifiers in Huntington disease: a replication study. PLOS Currents, 2011, 3, RRN1247.	1.4	20
112	The personal experience of parenting a child with Juvenile Huntingtonâ€™s Disease: perceptions across Europe. European Journal of Human Genetics, 2013, 21, 1042-1048.	1.4	19
113	One-year safety and tolerability profile of pridopidine in patients with Huntington disease. Neurology, 2013, 80, 1086-1094.	1.5	19
114	Stability effects on results of diffusion tensor imaging analysis by reduction of the number of gradient directions due to motion artifacts: an application to presymptomatic Huntingtonâ€™s disease. PLOS Currents, 2011, 3, RRN1292.	1.4	19
115	Cocaineâ€•and amphetamineâ€•regulated transcript is increased in Huntington disease. Movement Disorders, 2007, 22, 1952-1954.	2.2	18
116	Natural variation in sensoryâ€•motor white matter organization influences manifestations of Huntington's disease. Human Brain Mapping, 2016, 37, 4615-4628.	1.9	18
117	Objective assessment of gait and posture in premanifest and manifest Huntington disease â€” A multi-center study. Gait and Posture, 2018, 62, 451-457.	0.6	18
118	Longitudinal task-negative network analyses in preclinical Huntingtonâ€™s disease. European Archives of Psychiatry and Clinical Neuroscience, 2014, 264, 493-505.	1.8	17
119	Unraveling corticobasal syndrome and alien limb syndrome with structural brain imaging. Cortex, 2019, 117, 33-40.	1.1	17
120	Defining pediatric huntington disease: Time to abandon the term Juvenile Huntington Disease?. Movement Disorders, 2019, 34, 584-585.	2.2	16
121	Utilisation of Healthcare and Associated Services in Huntingtonâ€™s disease: a data mining study. PLOS Currents, 2011, 3, RRN1206.	1.4	16
122	Two-Point Magnitude MRI for Rapid Mapping of Brown Adipose Tissue and Its Application to the R6/2 Mouse Model of Huntington Disease. PLoS ONE, 2014, 9, e105556.	1.1	15
123	Fast-to-Slow Transition of Skeletal Muscle Contractile Function and Corresponding Changes in Myosin Heavy and Light Chain Formation in the R6/2 Mouse Model of Huntingtonâ€™s Disease. PLoS ONE, 2016, 11, e0166106.	1.1	15
124	Gabapentin-lactam, but not gabapentin, reduces protein aggregates and improves motor performance in a transgenic mouse model of Huntington?s disease. Naunyn-Schmiedeberg's Archives of Pharmacology, 2004, 370, 131-9.	1.4	14
125	Olfactory screening of Parkinsonâ€™s Disease patients and healthy subjects in China and Germany: A study of cross-cultural adaptation of the Sniffinâ€™ Sticks 12-identification test. PLoS ONE, 2019, 14, e0224331.	1.1	14
126	Identification of symbol digit modality test score extremes in Huntington's disease. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2019, 180, 232-245.	1.1	13

#	Article	IF	Citations
127	The differential diagnostic value of a battery of oculomotor evaluation in Parkinson's Disease and Multiple System Atrophy. Brain and Behavior, 2021, 11, e02184.	1.0	13
128	Survival End Points for Huntington Disease Trials Prior to a Motor Diagnosis. JAMA Neurology, 2017, 74, 1352.	4.5	12
129	Combined cerebral atrophy score in Huntington's disease based on atlas-based MRI volumetry: Sample size calculations for clinical trials. Parkinsonism and Related Disorders, 2019, 63, 179-184.	1.1	12
130	Cerebrospinal Fluid Levels of Prodynorphinâ€Derived Peptides are Decreased in Huntington's Disease. Movement Disorders, 2021, 36, 492-497.	2.2	12
131	Impact of the control for corrupted diffusion tensor imaging data in comparisons at the group level: an application in Huntington disease. BioMedical Engineering OnLine, 2014, 13, 128.	1.3	11
132	Intact sensory-motor network structure and function in far from onset premanifest Huntingtonâ€™s disease. Scientific Reports, 2017, 7, 43841.	1.6	11
133	High-resolution respirometry of fine-needle muscle biopsies in pre-manifest Huntingtonâ€™s disease expansion mutation carriers shows normal mitochondrial respiratory function. PLoS ONE, 2017, 12, e0175248.	1.1	11
134	Motor speech disorders in the nonfluent, semantic and logopenic variants of primary progressive aphasia. Cortex, 2021, 140, 66-79.	1.1	10
135	Assessment of Motor Symptoms and Functional Impact in Prodromal and Early Huntington Disease. PLOS Currents, 2011, 2, RRN1244.	1.4	10
136	Huntington's disease: new aspects on phenotype and genotype. Parkinsonism and Related Disorders, 2012, 18, S107-S109.	1.1	9
137	Identification of extreme motor phenotypes in Huntington's disease. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2017, 174, 283-294.	1.1	9
138	Current Pharmacological Management in Juvenile Huntingtonâ€™s Disease. PLOS Currents, 2012, 4, RRN1304.	1.4	9
139	Premotor Programming and Cortical Processing in the Cerebral Cortex. Brain, Behavior and Evolution, 1989, 33, 141-146.	0.9	8
140	Revisiting the Logan plot to account for non-negligible blood volume in brain tissue. EJNMMI Research, 2017, 7, 66.	1.1	8
141	A language-based sum score for the course and therapeutic intervention in primary progressive aphasia. Alzheimer's Research and Therapy, 2018, 10, 41.	3.0	8
142	Monitoring the Motor Phenotype in Huntingtonâ€™s Disease by Analysis of Keyboard Typing During Real Life Computer Use. Journal of Huntington's Disease, 2021, 10, 259-268.	0.9	7
143	Effect of Body Weight on Age at Onset in Huntington Disease. Neurology: Genetics, 2021, 7, e603.	0.9	7
144	HAP40 protein levels are huntingtin-dependent and decrease in Huntington disease. Neurobiology of Disease, 2021, 158, 105476.	2.1	7

#	Article	IF	Citations
145	Improving binding potential analysis in [11C]raclopride PET studies using cluster analysis. Medical Physics, 2004, 31, 902-906.	1.6	6
146	Meaningful and Measurable Health Domains in Huntingtonâ€™s Disease: Large-Scale Validation of the Huntingtonâ€™s Disease Health-Related Quality of Life Questionnaire Across Severity Stages. Value in Health, 2019, 22, 712-720.	0.1	6
147	Medication Use in Early-HD Participants in Track-HD: an Investigation of its Effects on Clinical Performance. PLOS Currents, 2016, 8, .	1.4	6
148	Graded cutaneous electrical vs thermal stimulation in humans shows different insular and cingulate cortex activation. Somatosensory & Motor Research, 2010, 27, 15-27.	0.4	5
149	Research priorities for rare neurological diseases: a representative view of patient representatives and healthcare professionals from the European Reference Network for Rare Neurological Diseases. Orphanet Journal of Rare Diseases, 2021, 16, 135.	1.2	5
150	Ubiquitination and the proteasome rather than caspaseâ€3â€mediated Câ€terminal cleavage are involved in the EAAT2 degradation by staurosporineâ€induced cellular stress. Journal of Neurochemistry, 2021, 157, 1284-1299.	2.1	4
151	Predicting disease progression in behavioral variant frontotemporal dementia. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12262.	1.2	4
152	Validating Automated Segmentation Tools in the Assessment of Caudate Atrophy in Huntingtonâ€™s Disease. Frontiers in Neurology, 2021, 12, 616272.	1.1	3
153	How to Arrange Follow-Up Time-Intervals for Longitudinal Brain MRI Studies in Neurodegenerative Diseases. Frontiers in Neuroscience, 2021, 15, 682812.	1.4	3
154	Huntington's disease. , 2005, , 847-860.		2
155	I9â€...The size of the CAG-expansion mutation can be predicted in hd based on phenotypic data using a machine learning approach. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, A62.1-A62.	0.9	2
156	An International Validation of a Clinical Tool to Assess Carersâ€™ Quality of Life in Huntingtonâ€™s Disease. Frontiers in Psychology, 2019, 10, 1658.	1.1	2
157	J01â€...Effects of IONIS-HTTRX (RG6042) in patients with early huntingtonâ€™s disease, results of the first htt-lowering drug trial. , 2018, , .		2
158	Eighth International Chorea-Acanthocytosis Symposium: Summary of Workshop Discussion and Action Points. Tremor and Other Hyperkinetic Movements, 2017, 7, 428.	1.1	2
159	F25â€...Huntingtonâ€™s disease health-related quality of life questionnaire (HDQOL): further validation. , 2018, , .		1
160	Etiology, Pathology, and Pathogenesis. Blue Books of Neurology, 2010, , 417-431.	0.1	0
161	Interview: Following a standard of care for Huntingtonâ€™s disease. Neurodegenerative Disease Management, 2012, 2, 159-163.	1.2	0
162	B30â€...Integrated mitochondrial function in human fine-needle muscle biopsies of huntingtonâ€™s disease mutation carriers and in tissues of HdhQ111 mice. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, A19.3-A20.	0.9	0

#	Article	IF	Citations
163	M3â€…Study participation but not the antidepressant bupropion reduces apathy in huntingtonâ€™s disease. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, A102.1-A102.	0.9	0
164	I32â€…Using the global clinical research platform of enroll-hd to facilitate the enrollment of premanifest huntington disease (HD) participants in clinical trials. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, A70.1-A70.	0.9	0
165	D22â€…Compensation in preclinical huntingtonâ€™s disease: evidence from the track-on HD study. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, A42.2-A42.	0.9	0
166	F13â€…Assessment of the performance of a modified motor scale as applied to juvenile onset huntingtonâ€™s disease. , 2018, , .		0
167	A34â€…Mitochondrial respiration is limited by atp-production in the skeletal muscle of the R6/2 hd mouse model. , 2018, , .		0
168	A07â€…Huntingtin-dependent stability of HAP40 and decreased HAP40 levels in huntingtonâ€™s disease. , 2021, , .		0
169	F36â€…DXA, BIA, anthropometry and skin folds methodology in body composition. , 2021, , .		0
170	F49â€…Machine learning approach in analysis of enroll-hd data for suicidality prediction in huntington disease. , 2018, , .		0
171	Factors influencing atrophy progression in primary progressive aphasia. Alzheimer's and Dementia, 2021, 17, .	0.4	0
172	Title is missing!. , 2019, 14, e0224331.		0
173	Title is missing!. , 2019, 14, e0224331.		0
174	Title is missing!. , 2019, 14, e0224331.		0
175	Title is missing!. , 2019, 14, e0224331.		0
176	241â€… Intrathecal antisense oligonucleotide delivery in HD: experience from RG6042 programme and best practice considerations. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A83.1-A83.	0.9	0